4 weeks ago
5
MarketBeat
Tue, February 24, 2026 astatine 6:48 AM CST 6 min read
ConvaTec Group (LON:CTEC) executives told investors the institution delivered “strong” 2025 results and expects different twelvemonth of nett maturation successful 2026, portion preparing to update its longer-term maturation ambitions astatine a Capital Markets Day successful aboriginal April.
Management said 2025 marked the 5th consecutive twelvemonth of integrated gross maturation wrong the company’s people range, supported by 8 caller merchandise launches. The radical besides posted its 4th consecutive twelvemonth of operating borderline enlargement and a 2nd twelvemonth of double-digit earnings-per-share growth, driven by higher operating profit, little concern costs, and a reduced stock number pursuing a $300 cardinal buyback.
→ Gold and Silver Pulled Back—Here’s Why the Bull Case Is Intact
New CFO Fiona Ryder said integrated gross maturation successful 2025 was “broad-based crossed each 4 categories.” Excluding InnovaMatrix, gross maturation was 6.4%. Operating borderline expanded by 110 ground points to 22.3%, and EPS accrued 16%.
Category show discussed connected the telephone included:
-
Advanced Wound Care: Sales roseate 4.1% excluding InnovaMatrix (flat including it). Ryder cited bully maturation successful North America and Latin America, with improved show successful Europe during the 2nd half. AQUACEL Ag+ Extra posted different coagulated year, and ConvaFoam was described arsenic “gaining share.”
-
Ostomy Care: Organic maturation was 4.5%. Management highlighted stronger-than-expected show from Esteem Body and maturation from an updated Esenta accessories range. Executives besides noted a archetypal U.S. radical purchasing enactment (GPO) triumph successful 5 years, followed by different triumph aft year-end.
-
Continence Care: Organic maturation was 6.6%, driven by higher U.S. volumes and a increasing premix of ConvaTec-branded products. Hydrophilic products were again much than 60% of the category’s revenue, and planetary markets contributed much than 1 percent constituent to growth.
-
Infusion Care: Organic maturation was 12.5%. Ryder said request successful diabetes remained beardown arsenic automated insulin transportation penetration increased, portion non-diabetes maturation was led by infusion sets for AbbVie’s Parkinson’s illness therapy. Other therapies roseate to 15% of infusion attraction revenue, up from astir 10% successful 2024.
→ Opendoor Pops After Earnings, But the Big Question Hasn’t Changed
Management repeatedly returned to InnovaMatrix, citing “significant marketplace uncertainty” successful tegument substitutes. Ryder said InnovaMatrix income declined by astir $30 cardinal year-over-year to $69 million, with a sharper slowdown successful the 2nd half.
English (CA) · 
English (US) · 
Spanish (MX) ·